UK Biobank whole genome sequencing project: money paid by four pharmaceutical companies, per genome
£100 million
USD per whole genome, industry share, UK
“The £200 million whole genome sequencing project is being created, forming a partnership of pharmaceutical firms and health experts which will examine and sequence the genetic code of 500,000 volunteers at the UK Biobank ... A further £100 million has come from four of the world’s leading biopharmaceutical and healthcare companies Amgen, AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson.”
- Kind of source
- The payer's or seller's own page
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- Money four companies put toward sequencing 500,000 genomes (the other £100 million came from UKRI and Wellcome): it paid for producing the data, so it is a cost, not a licence price. The page does not state the companies' access terms or each company's share.
- Arithmetic
- £100,000,000 / 500,000 genomes = £200 per genome; £200 x 1.3385 USD per GBP (rate of 2026-11-06, api.frankfurter.dev) = $267.70. The whole project: £200,000,000 / 500,000 = £400 per genome.
Used in
Kept as evidence; no figure on the platform is computed from it yet.